EXPRESSION OF THE VEGF, Glut1 AND 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE-3 AND -4 IN HUMAN CANCERS OF THE LUNG, COLON AND STOMACH
DOI: http://dx.doi.org/10.30970/sbi.0301.018
Abstract
Expression of vascular endothelial growth factor (VEGF), glucose transporter Glut1 and two members of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase family (PFKFB-3 and PFKFB-4) in lung, colon and gastric cancers was studied. We have shown that expression of VEGF and glucose transporter Glut1 mRNA significantly increased in lung and colon cancers and much less – in gastric cancers comparing with corresponding normal tissues counterparts. However, expression of mRNA of glucose transporter Glut1 was increased in all tested cancers more distinctly as compared with mRNA for VEGF. Moreover, we have shown that PFKFB-3 and -4 mRNA were overexpressed in different cancers, but much more marked changes were observed in the lung and colon. PFKFB-4 protein level was also increased in different cancers being more clearly induced in the lung cancer. However, normal tissue counterparts from colon and stomach have much higher levels of PFKFB-4 protein, as compared to the lung. Thus, our data demonstrated that VEGF, glucose transporter Glut1, PFKFB-3 and PFKFB-4, known HIF-dependent genes, are overexpressed in malignant tumors from lung, colon and stomach and thus can participate in regulation of tumor growth.
Keywords
Full Text:
PDFReferences
1. Atsumi T., Chesney J., Metz C. et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (iPFK-2; PFKFB3) in human cancers. Cancer Research, 2002; 62(20): 5881-5887. | |
| |
2. Atsumi T., Nishio T., Niwa H. et al. Expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase/PFKFB3 isoforms in adipocytes and their potential role in glycolytic regulation. Diabetes, 2005; 54(12): 3349-3357. | |
| |
3. Bitlon R.L., Booker G.W. The subtle side to hypoxia inducible factor (HIFalpha) regulation. European Journal of Biochemistry, 2003; 270(5): 791-798. | |
| |
4. Obach M., Navarro-Sabaté A., Caro J. et al. 6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. J. Biol. Chem, 2004; 279(51):53562-53570. | |
| |
5. Chen J., Zhao S., Nakada K. et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. American Journal of Patholology, 2003; 162(4): 1283-1291. | |
| |
6. Chesney J. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis. Current Opinion Clinical Nutritional Metabolism Care, 2006; 9(5): 535-539. | |
| |
7. Denko N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumor. Nat. Rev. Cancer, 2008; 8: 705-713. | |
| |
8. Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors. Nature Medicine, 2003; 9(6): 669-676. | |
| |
9. Hirata T., Watanabe M., Miura S. et al. Inhibition of tumor cell growth by a specific 6-phosphofructo-2-kinase inhibitor, N-bromoacetylethanolamine phosphate, and its analogues. Biosciences. Biotechnology and Biochemistry, 2000; 64(10): 2047-2052. | |
| |
10. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of National Cancer Institute, 2001; 93: 266-276. | |
| |
11. Hopfl G., Ogunshola O., Gassmann M. HIFs and tumors - causes and consequences. American Journal of Pathology, 2004; 286(4): R608-R623. | |
| |
12. Lu H., Forbes R.A., Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. Journal of Biological Chemistry, 2002 277(26): 23111-23115. | |
| |
13. Minchenko A.G., Leshchinsky I., Opentanova I. et al. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Journal of Biological Chemistry, 2002; 277(8): 6183-6187. | |
| |
14. Minchenko O., Opentanova I., Caro J. Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-3 gene family (PFKFB-1-4) expression in vivo. FEBS Letters, 2003; 554(3): 264-270. | |
| |
15. Minchenko O., Opentanova I., Minchenko D.O. et al. Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 gene via hypoxia-inducible factor-1alpha activation. FEBS Letters, 2004; 576(1): 14-20. | |
| |
16. Okar D.A., Lange A.J. Fructose-2,6-biphosphate and control of carbohydrate metabolism in eukaryotes. Biofactors, 1999; 10(1): 1-14. | |
| |
17. Okar D.A., Manzano A., Navarro-Sabate A. et al. PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends of Biochemical Science, 2001; 26 (1): 30-35. | |
| |
18. Rider M.H., Bertrand L., Vertommen D. et al. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-head with a bifunctional enzyme that controls glycolysis. Biochemical Journal, 2004; 381 (Pt. 3): 561-579. | |
| |
19. Ryan H.E., Poloni M., McNulty W. et al. Hypoxia-inducible factor-1 is a positive factor in solid tumor growth. Cancer Research, 2000; 60(15): 4010-4015. | |
| |
20. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nature Review. Molecular and Cellular Biology, 2004; 5(5): 343-354. | |
| |
21. Semenza G.L. Targeting HIF-1 for cancer therapy. Nature Review Cancer, 2003; 3(2): 212-225. | |
| |
22. Walenta S., Salameh A., Lyng H. et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. American Journal of Patholology, 1997; 150(3): 409-415. | |
| |
23. Wenger R.H. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB Journal, 2002; 169(10): 1151-1162. | |
| |
24. Wiesener M.S., Jurgensen J.S., Rosenberger C. et al. Widespread hypoxia-inducible expression of HIF-2 alpha in distinct cell populations of different organs. FASEB Journal, 2003; 17(2): 271-273. | |
| |
25. Wykoff C.C., Pugh C.W., Maxwell P.H. et al. The HIF pathway: implications for patterns of gene expression in cancer. Novartis Found Symposium, 2001; 240: 212-225. | |
Refbacks
- There are currently no refbacks.
Copyright (c) 2009 Studia biologica
This work is licensed under a Creative Commons Attribution 4.0 International License.